Diethyltoluamide
CAS 134-62-3
Diethyltoluamide (CAS 134-62-3) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 72 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 17957.81 nM | 9 | - |
| - | AC50 | 33191.333333333336 nM | 3 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Diethyltoluamide used for in pharmaceutical contexts?
Diethyltoluamide (CAS 134-62-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Diethyltoluamide?
Diethyltoluamide has 72 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Balance disorder, Bladder disorder, Blood calcium decreased, Cognitive disorder, Constipation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Diethyltoluamide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Diethyl Toluamide (DEET) with EU status "prohibited".
What clinical phase is Diethyltoluamide in?
Diethyltoluamide is rendered with ChEMBL max phase 3.